Historical Valuation
Immunic Inc (IMUX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.95. The fair price of Immunic Inc (IMUX) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：0.66
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Immunic Inc (IMUX) has a current Price-to-Book (P/B) ratio of 5.48. Compared to its 3-year average P/B ratio of 1.16 , the current P/B ratio is approximately 372.74% higher. Relative to its 5-year average P/B ratio of 1.36, the current P/B ratio is about 303.44% higher. Immunic Inc (IMUX) has a Forward Free Cash Flow (FCF) yield of approximately -127.83%. Compared to its 3-year average FCF yield of -85.85%, the current FCF yield is approximately 48.90% lower. Relative to its 5-year average FCF yield of -69.12% , the current FCF yield is about 84.92% lower.
P/B
Median3y
1.16
Median5y
1.36
FCF Yield
Median3y
-85.85
Median5y
-69.12
Competitors Valuation Multiple
AI Analysis for IMUX
The average P/S ratio for IMUX competitors is 11.41, providing a benchmark for relative valuation. Immunic Inc Corp (IMUX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IMUX
1Y
3Y
5Y
Market capitalization of IMUX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IMUX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IMUX currently overvalued or undervalued?
Immunic Inc (IMUX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.95. The fair price of Immunic Inc (IMUX) is between NaN to NaN according to relative valuation methord.
What is Immunic Inc (IMUX) fair value?
IMUX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Immunic Inc (IMUX) is between NaN to NaN according to relative valuation methord.
How does IMUX's valuation metrics compare to the industry average?
The average P/S ratio for IMUX's competitors is 11.41, providing a benchmark for relative valuation. Immunic Inc Corp (IMUX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Immunic Inc (IMUX) as of Jan 10 2026?
As of Jan 10 2026, Immunic Inc (IMUX) has a P/B ratio of 5.48. This indicates that the market values IMUX at 5.48 times its book value.
What is the current FCF Yield for Immunic Inc (IMUX) as of Jan 10 2026?
As of Jan 10 2026, Immunic Inc (IMUX) has a FCF Yield of -127.83%. This means that for every dollar of Immunic Inc’s market capitalization, the company generates -127.83 cents in free cash flow.
What is the current Forward P/E ratio for Immunic Inc (IMUX) as of Jan 10 2026?
As of Jan 10 2026, Immunic Inc (IMUX) has a Forward P/E ratio of -1.34. This means the market is willing to pay $-1.34 for every dollar of Immunic Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Immunic Inc (IMUX) as of Jan 10 2026?
As of Jan 10 2026, Immunic Inc (IMUX) has a Forward P/S ratio of 0.00. This means the market is valuing IMUX at $0.00 for every dollar of expected revenue over the next 12 months.